Selective inhibitors of nlrp3 inflammasome

A compound of Formula (I):

• or a prodrug, hydrate, solvate, or pharmaceutically acceptable salt thereof, wherein:
• R1 is C3-C7 monocyclic cycloalkyl, polycyclic cycloalkyl, C5-C10 aryl, 8- to 12-membered heterocycloalkyl, or 5- to 6-membered heteroaryl, wherein the C3-C7 monocyclic cycloalkyl, polycyclic cycloalkyl, 8- to 12-membered heterocycloalkyl, or 5- to 6-membered heteroaryl is optionally substituted by one or more R6;
• R3 is H or C1-C4 alkyl optionally substituted with one or more R7;
• R4 is H, C1-C6 alkyl, —(CH2)0-3—(C3-C6 cycloalkyl), or —(CH2)0-3—C5-C6 aryl;
• R6 is C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, C3-C5 cycloalkyl, halo, oxo, —OH, —CN, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CH2F, —CHF2, or —CF3;
• R7 is —OR8, C5-C10 aryl, or 5- to 10-membered heteroaryl, wherein the C5-C10 aryl or 5- to 10-membered heteroaryl is optionally substituted by one or more R7S, wherein each R7S is independently C1-C6 alkyl, C1-C6 alkoxy, 5- to 10-membered heteroaryl, halo, —OH, —CN, —(CH2)0-3—NH2, —(CH2)0-3—NH(C1-C6 alkyl), —(CH2)0-3—N(C1-C6 alkyl)2, —CH2F, —CHF2, or —CF3;
• and
• R8 is C1-C6 alkyl or 5- to 7-membered heterocycloalkyl, wherein the C1-C6 alkyl or 5- to 7-membered heterocycloalkyl is optionally substituted by one or more R7S.